Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...
Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...
Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell in ...
Shares of Moderna Inc. MRNA slipped 2.31% to $41.83 Friday, on what proved to be an all-around mixed trading session for the ...
Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...
In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely to thrive the uncharted waters that were rising all around us. The early ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.82% ...
Shares of Moderna Inc. MRNA sank 0.09% to $42.82 Thursday, on what proved to be an all-around dismal trading session for the ...
The advisory committee, which met at the FDA’s request Thursday, did not reach a conclusion about the cause of a safety ...
Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback